In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Lilly agrees to buy Icos for $2.1bn

Executive Summary

Eli Lilly has entered into a definitive agreement to buy its biotech partner Icos in an all-cash deal. Lilly will pay $32 for each outstanding Icos share (a 21% premium to the 10-day pre-announcement market average), valuing the company at about $2.1bn.

Deal Industry
  • Biotechnology
  • Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Acquisition
    • Full Acquisition
    • Includes Contract
    • Payment Includes Cash for Equity

Related Companies